316 related articles for article (PubMed ID: 11673692)
1. Epidermal growth factor receptor biology (IMC-C225).
Kim ES; Khuri FR; Herbst RS
Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
Kim ES
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S80-4. PubMed ID: 15638964
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Herbst RS; Langer CJ
Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
[TBL] [Abstract][Full Text] [Related]
4. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
Herbst RS; Kim ES; Harari PM
Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
7. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
Tiseo M; Loprevite M; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):139-48. PubMed ID: 15032719
[TBL] [Abstract][Full Text] [Related]
10. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
Harari PM; Huang SM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
Buchsbaum DJ; Bonner JA; Grizzle WE; Stackhouse MA; Carpenter M; Hicklin DJ; Bohlen P; Raisch KP
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1180-93. PubMed ID: 12419447
[TBL] [Abstract][Full Text] [Related]
12. Growth factors and their receptors: new targets for prostate cancer therapy.
Barton J; Blackledge G; Wakeling A
Urology; 2001 Aug; 58(2 Suppl 1):114-22. PubMed ID: 11502465
[TBL] [Abstract][Full Text] [Related]
13. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
Harari PM; Huang SM
Semin Radiat Oncol; 2001 Oct; 11(4):281-9. PubMed ID: 11677653
[TBL] [Abstract][Full Text] [Related]
14. [EGF receptors in urological cancer. Molecular basis and therapeutic involvements].
Paule B; Brion N
Ann Med Interne (Paris); 2003 Nov; 154(7):448-56. PubMed ID: 14732836
[TBL] [Abstract][Full Text] [Related]
15. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Rossi A; Bria E; Maione P; Palazzolo G; Falanga M; Gridelli C
Rev Recent Clin Trials; 2008 Sep; 3(3):217-27. PubMed ID: 18782080
[TBL] [Abstract][Full Text] [Related]
16. [Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
Tamura T
Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):233-6. PubMed ID: 11904986
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy.
Herbst RS; Shin DM
Cancer; 2002 Mar; 94(5):1593-611. PubMed ID: 11920518
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab in cancers of the lung and head & neck.
Kim ES; Vokes EE; Kies MS
Semin Oncol; 2004 Feb; 31(1 Suppl 1):61-7. PubMed ID: 14981582
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase.
Molli PR; Adam L; Kumar R
Clin Cancer Res; 2008 Oct; 14(19):6161-70. PubMed ID: 18829495
[TBL] [Abstract][Full Text] [Related]
20. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]